What's breaking now, across thousands of outlets.
Months after the FDA rejected its treatment for a rare light-sensitivity disease, the biotech claimed success in a Phase 3 trial and now plans to re-engage regulators.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.
Research at the University of Missouri could lead to new therapies for people with amyotrophic lateral sclerosis (ALS) and other motor neuron diseases.
In what is thought to be the first study of its kind, researchers from Cardiff University and Imperial College London examined both gut bacteria and chemicals.
(MedPage Today) -- It's traditionally been frowned upon for us doctors to talk with patients about voting. But at a time of growing crisis in healthcare, clinicians now face an important decision in…
Between 1999 and 2020, breast cancer mortality declined across rural and urban populations, but by 2005, mortality among rural patients surpassed that of urban patients and after 2013 remained…
Urban residents with more greenery within 100 meters (328 feet) of their homes have a 20% lower risk of developing dementia over time, according to a new study from Stockholm University and Karolinska…
